Spain Continuous Glucose Monitoring Market Size, Share, Opportunities, And Trends By Type (Real-Time CGM, Intermittently CGM), By Gender (Male, Female), By Age (Greater than 20, Less than 20), By Application (Diabetic Patients, Critical Patients), And By End User Industry (Hospitals, Diagnostic Centers and Clinics, Home care) - Forecasts From 2025 To 2030

Spain’s continuous glucose monitoring market is expected to surpass US$114.025 million by 2030, growing at a 10.39% CAGR from US$69.552 million in 2025.

Spain Continuous Glucose Monitoring Highlights

• Diabetes Prevalence: Rising diabetes cases drive demand for CGM devices in Spain.
• Technological Advancements: Smaller, more accurate CGM devices enhance user adoption and experience.
• Reimbursement Support: Increased national health system reimbursements boost CGM accessibility.
• Patient Awareness: Growing awareness of glycemic control fuels CGM market expansion.

The Spanish (continuous glucose monitoring) CGM market is booming due to the strong prevalence of diabetes and a huge focus on glycemic control. Technological advancements, like smaller sensors and longer wear times, are also improving patient experience and driving market expansion. For instance, in February 2024, Dexcom, Inc. launched its new CGM system, Dexcom ONE+, for people with diabetes worldwide. In some countries, Dexcom ONE+ supersedes the previous generation Dexcom ONE sensor.

Moreover, the integration of CGM devices with digital health platforms facilitates data sharing, remote monitoring, and personalized diabetes management. Government reimbursement policies and intense competition among major players greatly affect market dynamics.

Virtual Real-time, Diabetes Self-Management Program (DSMES) is a Spanish-language interactive group workshop facilitated through Zoom or other virtual platforms. It is the support program acknowledged by the American Diabetes Association for adults living with type 2 diabetes.

The Spanish CGM market is driven by several factors, including the high prevalence of diabetes, advancements in CGM technology, and growing awareness and acceptance of these devices among patients and healthcare professionals. Additionally, government initiatives supporting diabetes management and a strong emphasis on improving patient outcomes through tight glycemic control contribute to the market's growth.

The market is booming due to the strong prevalence of diabetes and a huge focus on glycemic control. Technological advancements, like smaller sensors and longer wear times, are also improving patient experience and driving market expansion. In February 2024, DexCom, Inc. launched its new CGM system, Dexcom ONE+, for people with diabetes worldwide. In some countries, Dexcom ONE+ supersedes the previous generation Dexcom ONE sensor.

Moreover, the integration of CGM devices with digital health platforms facilitates data sharing, remote monitoring, and personalized diabetes management. Government reimbursement policies and intense competition among major players greatly affect market dynamics. Virtual real-time, Diabetes Self-Management Program (DSMES) is a Spanish language interactive group workshop facilitated through Zoom or other virtual platforms. It is the support program acknowledged by the American Diabetes Association for adults living with type 2 diabetes.

Spain Continuous Glucose Monitoring Market Drivers:

• The rising prevalence of diabetes is accelerating the adoption of continuous glucose monitoring in Spain.

As the number of people with diabetes grows, so does the demand for effective diabetes management tools. CGM devices offer valuable insights into blood glucose levels, enabling patients and healthcare providers to make informed decisions about diet, exercise, and medication.

Further, in Spain, many studies have tried to define the prevalence of diabetes at various levels. Most of them revealed prevalence rates of diabetes between 10% and 15%, showing that the set estimates have probably been surpassed. As per the IDF Diabetes Atlas, in 2021, people with diabetes were 5,141.3 thousand in Spain 2021, which is anticipated to increase to 5,576.0 thousand in 2030. Amongst this, Type 1 diabetes in children and adolescents was 9.7 thousand in 2021.

The Spanish CGM market for males is growing significantly. Several factors are contributing to this growth. For instance, the prevalence of diabetes in Spain, especially type 2, requires effective blood sugar management. This is where CGM devices come in, providing real-time data for both patients and healthcare providers.

The male population (% of total population) in Spain was at 49.1 % in 2023, as gathered from the World Bank collection of development indicators compiled from officially recognized sources.

Moreover, technological advancements within CGM have resulted in increasingly accurate, more user-friendly, and less obtrusive devices, which improve the patient experience and compliance. The improved awareness and acceptability of CGM among healthcare providers as well as among patients are further fueling the market. The table below represents some of the popular CGM products available in the Spanish market.

The Spanish CGM market for adults 20 years of age and older is growing substantially, driven by several factors. Leading the way is the increasing prevalence of diabetes, especially type 2, among this population. This growing diabetic population generates significant demand for CGM devices, which are essential for the proper control of blood sugar levels and, therefore, reduction in the likelihood of complications associated with diabetes. Following this, 11.8% of Spanish people aged 20 and above are anticipated to have diabetes by 2030.

• Rising demand for real-time CGM

Real-Time CGM (rtCGM) is the dominant segment due to its advanced functionality, including continuous glucose data transmission, predictive alerts, and integration with insulin delivery systems. This segment is particularly critical for managing Type 1 diabetes and increasingly Type 2 diabetes, driven by technological advancements and supportive healthcare policies. Below, we explore the major drivers propelling the rtCGM segment in Spain, supported by recent industry developments and targeted at industry experts.

Spain has a high diabetes prevalence, estimated at 14.8% of the adult population in 2023, with approximately 5.1 million adults affected. The increasing incidence of Type 1 and Type 2 diabetes fuels demand for rtCGM systems, which provide continuous monitoring and real-time alerts to manage glycemic variability effectively. This driver is particularly significant as RT-CGM systems improve patient outcomes by reducing hypoglycemic and hyperglycemic events, making them essential for diabetes management.

Recent innovations in RT-CGM devices, such as smaller sensors, faster warm-up times, and integration with insulin pumps, have enhanced user adoption. For instance, the Dexcom G7, launched in Spain in 2023, features a 60% smaller sensor and a 30-minute warm-up period, improving patient comfort and usability. Similarly, the Medtronic MiniMed 780G system with Simplera Sync, introduced in January 2024, offers automated insulin adjustments and predictive glucose alerts, driving market growth by addressing patient needs for precision and convenience.

Spain’s national health system has significantly expanded reimbursement for rtCGM devices since 2021, particularly for Type 1 diabetes patients and, more recently, for Type 2 patients on intensive insulin therapy. This policy shift has made RTCGM systems more accessible, driving adoption among a broader patient base. The inclusion of rtCGM in the Common Package of Benefits, announced in June 2021, has been a pivotal development, reducing out-of-pocket costs and increasing market penetration.

The integration of RT-CGM systems with digital health platforms, such as Glooko and Tidepool, has enhanced their utility in Spain. These platforms enable real-time data sharing with healthcare providers, facilitating remote monitoring and personalized treatment plans. For example, Glooko’s integration with the Dexcom G7, announced in 2024, allows clinicians to access patient glucose data seamlessly, improving clinical decision-making and patient engagement. This driver strengthens rtCGM’s position in Spain’s healthcare landscape.

The rtCGM segment dominates the Spain CGM market due to its ability to provide continuous, real-time glucose monitoring, predictive alerts, and integration with automated insulin delivery systems. Key drivers include the rising diabetes prevalence, technological advancements in devices like the Dexcom G7 and Medtronic MiniMed 780G, expanded reimbursement policies, and integration with digital health platforms. These factors, supported by Spain’s healthcare infrastructure and increasing focus on diabetes management, position rtCGM for sustained growth through 2030, offering significant opportunities for industry stakeholders.

Spain Continuous Glucose Monitoring Market Restraints

High Costs of CGM Devices

• Despite reimbursement progress, the high upfront and ongoing costs of CGM devices remain a barrier, particularly for patients without full coverage. rtCGM systems, such as the Dexcom G7 or Medtronic MiniMed 780G, are more expensive than isCGM options like the FreeStyle Libre 3, limiting adoption among cost-sensitive patients. Out-of-pocket expenses for sensors and transmitters can deter long-term use, especially for Type 2 diabetes patients with less severe needs.
• Limited Awareness in Rural and Elderly Populations

Awareness of CGM benefits is lower among rural populations and elderly patients, who may lack access to diabetes education or specialized healthcare. This is compounded by limited digital literacy among older demographics, hindering the adoption of CGM systems that rely on smartphone integration. While urban centers like Madrid and Barcelona see high uptake, rural areas lag, constraining market growth.

• Sensor Discomfort and User Compliance Issues

Some patients experience discomfort from CGM sensors, leading to inconsistent use or discontinuation. Issues such as skin irritation or the need for frequent sensor replacement (every 7-14 days) can affect compliance, particularly for isCGM users who must manually scan devices. Although advancements like smaller sensors in the FreeStyle Libre 3 and Dexcom G7 address this, user experience challenges persist, impacting market expansion.

Spain Continuous Glucose Monitoring Market Segmentation Analysis:

• By application, diabetes patients are expected to witness significant growth in Spain’s continuous glucose monitoring market.

The rising prevalence of diabetes is increasing the continuous glucose monitoring market in Spain. Wearable minimally invasive CGM sensors are transforming diabetes care by providing continuous blood glucose (BG) concentration readings in real continuously.

Moreover, as of 2021, the number of people with type 1 diabetes in Spain was 5,141.3 per thousand people per year and will rise to 5,576.0 by 2030. Additionally, around 13.8% of Spanish adults are diabetic, of which about 6% are undiagnosed. An increase in the genetic predisposition for diabetes and the rising ageing population are accounting for the rising incidence of the disease. The need for diabetes devices is further fueled by the increased risk of diabetes that comes with ageing.

Further, the Spanish population’s shifting dietary and lifestyle patterns are another main cause for the rise in diabetes. More sedentary lifestyles, increasing consumption of processed foods, and sugary drinks are contributing to the rising prevalence of obesity and type 2 diabetes.

The Spanish Government and healthcare institutions have taken a number of initiatives to curb rising diabetes incidences. These programs include awareness campaigns, educational programs, and increased access to power in diabetes management, including diabetes devices. Additionally, DexCom launched its Dexcom ONE+ real-time CGM system in Spain, Belgium, and Poland in February 2024.

• By end-user, hospitals are witnessing substantial market growth

There has been a consistent increase in the demand for CGM devices by hospitals in Spain. This increase is due to the rise in the number of diabetic patients in the country and improved public awareness about the advantages of CGM technology in managing diabetes. By lowering the risks involved with conventional finger-prick techniques, CGM devices assist patients and healthcare professionals in monitoring glucose levels in real-time.

Moreover, the Spanish Government has also launched several initiatives along with real-time CGM devices in the Common Package of Benefits provided by the Spanish National Health System. It is important for reducing the risks associated with severe hypoglycemia in adults with type 1 diabetes. Further, modernizing facilities and incorporating cutting-edge medical technologies have led to high investments in hospitals throughout Spain. For instance, 9.7% of GDP was spent on healthcare in Spain in 2022. These facilities include cutting-edge patient monitoring systems and diagnostic tools, including CGM devices, which, in the management of a long-term illness, can help in the proper treatment and diagnostics, such as diabetes.

Additionally, many patients benefit from CGM technology as hospitals are using more advanced equipment with state-of-the-art diagnostics and monitoring. This is important in public healthcare setups that are expanding the availability of equipment in hospitals, boosting market expansion.

Spain Continuous Glucose Monitoring Market Key Developments:

• Dexcom ONE+ Launch (February 2025): Dexcom launched the ONE+ CGM system in Spain, offering improved usability and real-time glucose monitoring.
• Medtronic MiniMed 780G Launch (January 2024): The MiniMed 780G system from Medtronic Diabetes, which uses the Simplera Sync sensor, received CE Mark clearance, making it the first disposable, fingerstick-free CGM in the world. Designed for users seven years of age and up, this novel device features a straightforward two-step insertion method and is scheduled for limited distribution in Europe in the spring of 2024, with a phased commercial launch to follow in the summer of the same year.
• Abbott FreeStyle Libre 3 Expansion (2022): Abbott expanded FreeStyle Libre 3 availability in Spain, featuring smaller sensors and enhanced connectivity.

 

• Reimbursement Policy Enhancements (2023): Spain's national health system expanded CGM reimbursement, increasing adoption among diabetic patients.

The Spain continuous glucose monitoring Market is analyzed into the following segments:

• By Application
  • Diabetes Patients
  • Critical Patients
• By End-User
  • Hospitals
  • Diagnostic Center and Clinics
  • Home Care

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. SPAIN CONTINUOUS GLUCOSE MONITORING MARKET BY APPLICATION

4.1. Introduction

4.2. Diabetes Patients

4.3. Critical Patients

5. SPAIN CONTINUOUS GLUCOSE MONITORING MARKET BY END-USER INDUSTRY

5.1. Introduction

5.2. Hospitals

5.3. Diagnostic Centers & Clinics

5.4. Home Care

6. COMPETITIVE ENVIRONMENT AND ANALYSIS

6.1. Major Players and Strategy Analysis

6.2. Emerging Players and Market Lucrativeness

6.3. Mergers, Acquisitions, Agreements, and Collaborations

6.4. Competitive Dashboard 

7. COMPANY PROFILES

7.1. Dexcom, Inc.

7.2. Abbott Laboratories

7.3. Medtronic

7.4. F. Hoffmann-La Roche Ltd.

7.5. Ascensia Diabetes Care

7.6. Insulet Corporation

7.7. Tandem Diabetes Care, Inc.

7.8. DiaMonTech AG

7.9. A. Menarini Diagnostics

Dexcom, Inc.

Abbott Laboratories

Medtronic

F. Hoffmann-La Roche Ltd.

Ascensia Diabetes Care

Insulet Corporation

Tandem Diabetes Care, Inc.

DiaMonTech AG

A. Menarini Diagnostics